CStone and EQRx Enter Global Strategic Partnership for Two Imm...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SUZHOU, China, Oct. 27, 2020 /PRNewswire-Asianet/ -- -CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside of Greater China -Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-...
Authors: LATEST ASIANET NEWS RELEASES